Glanbia stock
Price history
+36.73% over the period1 year: from €14.73 (November 17, 2025) to €20.14 (November 16, 2026), +36.73%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €20.14 |
| October 30, 2026 | €20.86 |
| September 30, 2026 | €19.65 |
| August 31, 2026 | €22.14 |
| July 31, 2026 | €22.98 |
| June 30, 2026 | €24.46 |
| May 29, 2026 | €20.86 |
| April 30, 2026 | €19.78 |
| March 31, 2026 | €16.95 |
| February 27, 2026 | €17.50 |
| January 30, 2026 | €16.23 |
| December 31, 2025 | €14.59 |
| November 28, 2025 | €14.79 |
| November 17, 2025 | €14.73 |
At a glance
The company
Produces sports nutrition and lifestyle nutrition products, dairy and non-dairy nutritional ingredients, and vitamin premixes
Latest results
Quarter to June 30, 2026
TickerLandia's take on Glanbia
- Priced in line with similar companies: trailing 12-month P/E 24 vs 25 (−4%) in a group of 10.
- “Most upside for analysts” (Ireland): No. 3 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.76% from the 52-week high
Analysts · 10 analysts
Average target€23.98+19.05% vs. price
Buy 5 · Hold 3 · Sell 2 · Buy
TickerLandia Fingerprint: Glanbia
Compared with similar companies: high risk.
Financials and price compared with 58 companies in the packaged foods industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage55
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 13.0 40 EV/EBITDA 11.6 55 P/E (trailing 12 months) 24.1 59 Price/book 2.86 66 Price/sales 1.18 56 Profitabilityaverage51
How much it earns on revenue and capital.
Metric Value Position in group Net margin 5.8% 58 ROE 12.0% 55 Gross margin 27.3% 34 Operating margin 9.6% 44 ROA 6.2% 63 Earnings stabilityaverage43
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.4% 25 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −12.76% 1 Revenue growth (year over year) +7.90% 77 Earnings growth (year over year) +63.70% 89 Financial strengthaverage58
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.53 54 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.57 72 Interest coverage 12.0 61 Debt/equitycounts in reverse: lower means more financial strength 0.64 46 Dividendaverage49
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 53.7% 42 Consecutive dividend years at least 27 years 72 Dividend yield 2.2% 33 Market momentumaverage57
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −0.90% 38 1-year return +32.32% 77 Riskhigh70
How much the price swings.
Metric Value Position in group Volatility (60 days) 43.9% 87 Maximum drawdown (12 months) 24.9% 53
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Glanbia is in line with similar companies
Glanbia's P/E (trailing 12 months): 24.1, in line with the median of a group of 10 similar companies (25.0).
Compared with 10 similar companies
| Metric | Glanbia | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 24.1 | Middle | |
| Forward P/E | 13.0 | Middle | |
| Operating margin | 9.6% | Middle | |
| ROE | 12.0% | Middle | |
| Debt/equity | 0.64 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Glanbia. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.08B
Latest quarter · Q2 2026
Net income
$153.8M
Latest quarter · Q2 2026
Quarterly net margin
7.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €4.84B
- P/E
- 24.1
- EPS
- €0.83
- Volume
- 589.52K
- Daily trading
- €9.59M
- Dividend yield
- 2.21%
- Last ex-dividend on August 20, 2026
How Glanbia is changing
All resultsRevenue fell 3.3% a year on average over the last 5 years
Operating margin rose from 4.8% to 8.9%
Profits turn into cash: free cash flow equal to 158% of net income
Returns
Glanbia returns with dividends
€1,000 invested in Glanbia 5 years ago, on November 16, 2021, would be worth €1,774 today with dividends reinvested: +77.37% in total, +12.15% per year. On price alone it would be €1,559 (+55.88%).
| Period | Glanbia | €1,000 becomes |
|---|---|---|
| 1 month | −0.98% | €990 |
| 6 months | −1.18% | €988 |
| Year to date | +38.04% | €1,380 |
| 1 year | +40.00% | €1,400 |
| 3 years | +41.67% | €1,417 |
| 5 years | +77.37% | €1,774 |
| 10 years | +61.46% | €1,615 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Glanbia: technical analysis
Glanbia shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 18.9% below its all-time closing high (€24.84, July 3, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 49
- Between 30 and 70
- vs 200-session average
- −0.40%
Active signals
Death cross: the 50-session average has crossed below the 200-session average.
Support and resistance
Price areas where Glanbia has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€22.63+12.36%2 touches, last on September 9, 2026
- Resistance€22.03+9.38%4 touches, last on November 4, 2026
- Resistance€21.01+4.34%3 touches, last on October 15, 2026
- Last price€20.14
- Support€19.20−4.67%2 touches, last on November 9, 2026
- Support€18.64−7.43%3 touches, last on October 12, 2026
- Support€17.51−13.06%5 touches, last on April 10, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 43.9%
- Largest fall in the last year
- −24.88%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Glanbia: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Glanbia has been January: +2.98% on average, positive in 14 years out of 26. The weakest has been October: −0.53% on average, positive in 13 years out of 27. November, the current month, has been positive in 14 years out of 26 (+0.01% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.98% | +2.23% | 14 of 26 |
| February | +1.66% | +4.48% | 20 of 27 |
| March | +1.49% | −0.07% | 13 of 27 |
| April | +1.58% | 0.00% | 13 of 27 |
| May | +2.86% | +1.46% | 16 of 27 |
| June | +1.00% | −1.30% | 11 of 27 |
| July | +0.86% | +2.19% | 18 of 27 |
| August | +1.24% | +1.52% | 15 of 27 |
| September | −0.25% | +0.32% | 14 of 27 |
| October | −0.53% | −0.40% | 13 of 27 |
| November | +0.01% | +0.71% | 14 of 26 |
| December | +2.75% | +1.43% | 14 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Glanbia and its competitors
Athletes, gym users and everyday shoppers across the world make up the customer base of Glanbia plc, which reaches them through sports stores, supermarkets, drugstores, fitness centres and online platforms. The company develops sports and lifestyle nutrition products in powder, capsule, tablet, bar and ready-to-drink form, sold under brands including Optimum Nutrition, BSN, Isopure, Nutramino, think! and Amazing Grass.
- Headquarters
- Kilkenny, Ireland
- Employees
- 4,963
- Founded
- 1964
- Chief executive
- Hugh McGuire
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| GlanbiaGL9 | $5.35B | 9.6% | 24.1 | −1.18% |
| AAK AB (publ.)AAK | $4.59B | 10.5% | 13.1 | −32.35% |
| EmmiEMMN | $6.27B | 7.1% | 22.8 | +18.43% |
| Tate & LyleTATE | $3.28B | 11.6% | 37.4 | +4.94% |
| Ebro FoodsEBRO | $3.08B | 9.7% | 12.6 | +1.01% |
| Lerøy Seafood GroupLSG | $2.77B | 4.8% | 35.3 | −0.22% |
Same industry or related industries, similar size. Compare Glanbia with its competitors · Full profile
